Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Northover AM | Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. | 1990 | Agents Actions | pmid:2111079 |
McLeod J et al. | Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on substance P-induced histamine release from rat peritoneal mast cells. | 1990 | Agents Actions | pmid:1695435 |
Adolfs MJ et al. | PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion. | 1989 | Agents Actions | pmid:2540635 |
Neumann M and Kownatzki E | The effect of adherence on the generation of reactive oxygen species by human neutrophilic granulocytes. | 1989 | Agents Actions | pmid:2540640 |
Trebien HA and Calixto JB | Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. | 1989 | Agents Actions | pmid:2660497 |
Bekemeier H and Sänze JU | Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. | 1989 | Agents Actions | pmid:2476918 |
Jouquey S et al. | Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat. | 1988 | Agents Actions | pmid:2459935 |
Sanchez Crespo M and Nieto ML | Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. | 1989 | Agents Actions | pmid:2711927 |
Zijlstra FJ et al. | The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. | 1989 | Agents Actions | pmid:2711928 |
Nijkamp FP et al. | Role of platelet activating factor in the endotoxin induced tracheal hyperreactivity to histamine in the guinea pig. | 1989 | Agents Actions | pmid:2711929 |
Oliver JL et al. | Effect of PAF acether on oriented egg phosphatidylcholine multibilayers; interaction with cholesterol; comparison to lyso-PC and lyso-PAF. | 1989 | Agents Actions | pmid:2711930 |
Nieminen MM et al. | Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. | 1991 | Agents Actions | pmid:1862740 |
Jenei B et al. | Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). | 1991 | Agents Actions | pmid:1862750 |
Kantar A et al. | Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. | 1991 | Agents Actions | pmid:1862752 |
Carlson RP et al. | Pharmacologic modulation of PAF-induced mortality in mice. | 1987 | Agents Actions | pmid:3120513 |
Anderson GP et al. | Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. | 1988 | Agents Actions | pmid:3136622 |
Ramesha CS et al. | Identification and quantitation of PAF from psoriatic scales. | 1987 | Agents Actions | pmid:3687590 |
Friedlander G et al. | Renal effects of platelet-activating factor in the rat. | 1987 | Agents Actions | pmid:3687594 |
Taira M et al. | Lack of involvement of leukotriene and platelet activating factor in passive cutaneous anaphylaxis in rats. | 1988 | Agents Actions | pmid:3407549 |
Mastacchi R et al. | Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. | 1986 | Agents Actions | pmid:3518359 |
Kusner EJ et al. | Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. | 1987 | Agents Actions | pmid:3577957 |
Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
Perales J et al. | Neutralization of the oedematogenic activity of Bothrops jararaca venom on the mouse paw by an antibothropic fraction isolated from opossum (Didelphis marsupialis) serum. | 1992 | Agents Actions | pmid:1295374 |
Wong CW et al. | Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. | 1992 | Agents Actions | pmid:1414679 |
Tran A et al. | Separate induction of human blood platelet aggregation or cytotoxicity by different concentrations of PAF-acether and thrombin. | 1992 | Agents Actions | pmid:1414687 |
Northover AM | In vitro effects of PAF on venous endothelial cell actin disposition. | 1992 | Agents Actions | pmid:1509977 |
Okamoto H et al. | Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. | 1992 | Agents Actions | pmid:1388318 |
Miyagawa H et al. | The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils. | 1992 | Agents Actions | pmid:1456179 |
Lewis AJ et al. | The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. | 1984 | Agents Actions | pmid:6152379 |
Benveniste J | Platelet-activating factor (PAF-acether): present status. | 1981 | Agents Actions | pmid:6176101 |
Northover AM and Northover BJ | Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. | 1994 | Agents Actions | pmid:7942320 |
Tubaro E et al. | In vitro and in vivo impact of a new glycosphingolipid on neutrophils. | 1994 | Agents Actions | pmid:7879694 |
Canale P et al. | TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. | 1994 | Agents Actions | pmid:7879698 |
Raff GW et al. | Procoagulant property of platelet activating factor (PAF). | 1993 | Agents Actions | pmid:8273543 |
Meats JE et al. | Identification of phospholipase D (PLD) activity in mouse peritoneal macrophages. | 1993 | Agents Actions | pmid:8273553 |
Thomas TK et al. | Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat. | 1993 | Agents Actions | pmid:8273566 |
Glaser KB et al. | Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). | 1993 | Agents Actions | pmid:8273577 |
Kantar A et al. | Effect of PAF on human lymphocyte membranes: a fluorescence study. | 1993 | Agents Actions | pmid:8317302 |
Boonen GJ et al. | Activation of neutrophil migration by dioctanoyl-sn-glycerol and fMet-Leu-Phe is controlled by different pathways. | 1993 | Agents Actions | pmid:8317308 |
Murphy G | Report of the 14th meeting of the British Inflammation Research Association. Topic: cellular and molecular aspects of inflammatory bowel disease. | 1993 | Agents Actions | pmid:8480529 |
Perret BA et al. | Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. | 1981 | Agents Actions | pmid:6803540 |
Lecrubier C et al. | Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. | 1983 | Agents Actions | pmid:6858789 |
Jouvin-Marche E et al. | Platelet-activating factor (PAF-acether), an activator of neutrophil functions. | 1982 | Agents Actions | pmid:6299078 |
Caillard CG et al. | Hypotensive activity of PAF-acether in rats. | 1982 | Agents Actions | pmid:6299079 |
Vargaftig BB | Platelet-activating factor (PAF-acether) | 1982 | Agents Actions | pmid:7164939 |
Vargaftig BB et al. | Platelet-tissue interaction: role of platelet-activating factor (PAF-acether). | 1980 | Agents Actions | pmid:7270336 |
Heller R et al. | S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. | 1993 | Agents Actions | pmid:7517616 |
Czarnetzki BM and Benveniste J | Effect of synthetic PAF-acether on human neutrophil function. | 1981 | Agents Actions | pmid:7041568 |
Camussi G et al. | Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). | 1981 | Agents Actions | pmid:7041569 |
de Bernardis E et al. | Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. | 1994 | Agents Actions | pmid:7847181 |